Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Command Hospital, India
- Target Recruit Count
- 100
- Registration Number
- NCT02265276
- Locations
- 🇮🇳
Command Hospital, Panchkula, Haryana, India
The Practical Evidence of Antidiabetic Combination Therapy in Korea
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Kun-Ho Yoon
- Target Recruit Count
- 216
- Registration Number
- NCT02231021
- Locations
- 🇰🇷
Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
Neuroprotection of Pioglitazone in Acute Ischemic Stroke
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Taipei Medical University Shuang Ho Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT02195791
- Locations
- 🇨🇳
Taipei Medical Universtiy- Shuang Ho Hospital, New Taipei City, Taiwan
Obesity, Sleep Apnea, and Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT02192684
Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02183337
Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 246
- Registration Number
- NCT02181842
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02172235
Glycemic Durability After Metformin Failure
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 450
- Registration Number
- NCT02142309
- Locations
- 🇮🇹
Department of Geriatrics and Metabolic Diseases, Naples, Italy
🇮🇹Katherine Esposito, Naples, Italy
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT02133625
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 192
- Registration Number
- NCT02072096
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Southern New Hampshire Diabetes and Endocrinology, Nashua, New Hampshire, United States
🇺🇸Carolina Health Specialists, Myrtle Beach, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.